StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
ACH$2.77-2.46%
Fair $2.77+0.0%

ACH

Accendra Health, Inc.

Healthcare / Medical DistributionNYSE

$2.77

-0.07 (-2.46%)

Fairly Valued+0.0%Fair Value $2.77Fund rank 27/100 · Data gapFallback financials|
SA 29/D
F-Score: 3/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 25%

FCF escenarios

weak_data · normalized FCF $-21.2M · quality 47.3/100

Data gap 27/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 17/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

29/100

D

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

20/100

SEC 0%

Latest source: unknownPeriods: 18Warnings: 1unknown: 18
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is 2.4%, below the 5% threshold
Thesis & Journal · ACHLocal privado en este navegador · Accendra Health, Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$212M

P/E

N/A

•

EV/EBITDA

9.3x

↓

ROE

238.8%

↑

Gross Margin

46.7%

↓

Debt/Equity

-4.60

↓
52-Week Range$3
$2$10

TradingView lightweight chart

ACH price, volumen y niveles de valoración

Último $2.770Periodo -51.8%
Fair value: $2.770

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2008–2025 · 17 años de histórico normalizado

Revenue CAGR

-5.5%

FCF CAGR

—

FCF margin

-11.0%

FCF / Net income

0.28x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $2.76B · net income $-1.10B · FCF $-303.1M

2008-FY → 2025-FY

Gross margin

46.7%+36.4% pts

Operating margin

8.0%+5.5% pts

Net margin

-39.8%-41.1% pts

FCF margin

-11.0%— pts
MetricTTM
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Income Statement
Revenue$2.76B$2.76B$2.68B$2.55B$9.96B$9.79B$8.48B$9.21B$9.42B$9.32B$9.72B$9.77B$9.44B$9.07B$8.87B$8.63B$8.12B$8.04B$7.24B
Net Income$-1.10B$-1.10B$-362.7M$-41.3M$22.4M$221.6M$29.9M$-62.4M$-437.0M$72.8M$108.8M$103.4M$66.5M$110.9M$109.0M$115.2M$110.6M$104.7M$93.3M
EBITDA$219.8M$219.8M$-41.0M$342.4M$368.4M$459.1M$297.5M$189.8M$-250.4M$148.7M$255.0M$266.3M$222.9M$248.7M$236.4M$237.7M$225.1M$226.5M$202.7M
EPS-14.31-14.31-4.73-0.540.292.940.47-1.03——1.761.651.061.761.721.811.751.671.50
Gross Margin46.7%46.7%47.8%47.7%18.3%15.5%15.1%12.3%11.4%12.6%12.2%12.4%12.4%12.3%10.4%9.9%9.9%10.1%10.2%
Operating Margin8.0%8.0%7.4%8.4%2.8%3.8%2.4%0.8%-3.7%1.0%2.1%2.1%1.7%2.2%2.2%2.4%2.4%2.5%2.5%
Net Margin-39.8%-39.8%-13.5%-1.6%0.2%2.3%0.4%-0.7%-4.6%0.8%1.1%1.1%0.7%1.2%1.2%1.3%1.4%1.3%1.3%
Balance Sheet
Debt/Equity-4.60-4.603.292.512.87—1.383.263.180.89——0.610.210.220.230.24——
Current Ratio0.490.49—————————————————
Cash Flow
Free Cash Flow$-303.1M$-303.1M$-21.2M$562.2M$158.4M$83.2M$288.8M$123.7M$70.7M$22.2M$167.4M$249.7M$-52.2M$112.4M—————
Returns
ROE238.8%238.8%-61.9%-4.5%2.4%23.6%4.2%-13.5%-84.3%7.2%——6.7%10.8%11.2%12.5%12.9%13.6%13.5%
Valuation
P/E————68.86——————————————
EV/EBITDA9.339.33—10.3111.31——————————————
P/B——1.711.571.61——————————————
Growth & Yield
Revenue Growth3.1%3.1%5.0%-74.4%—15.4%-7.9%-2.2%1.1%-4.2%-0.5%3.5%4.1%2.3%2.8%6.2%1.1%11.0%—
EPS Growth-202.5%-202.5%-775.9%-286.2%—525.5%145.6%———6.7%55.7%-39.8%2.3%-5.0%3.4%4.8%11.3%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -58.0%

Total return

-58.0%

Start / end P/E

n/dx → n/dx

EPS bridge

-4.73 → -14.31

Residual

-58.0%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-58.0%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.